Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

New England Journal of Medicine, Journal Year: 2022, Volume and Issue: 387(1), P. 9 - 20

Published: June 5, 2022

Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable. Currently available HER2-directed therapies have been ineffective in patients with these "HER2-low" cancers.

Language: Английский

---

Pyroptosis: mechanisms and diseases

Signal Transduction and Targeted Therapy, Journal Year: 2021, Volume and Issue: 6(1)

Published: March 29, 2021

Abstract Currently, pyroptosis has received more and attention because of its association with innate immunity disease. The research scope expanded the discovery gasdermin family. A great deal evidence shows that can affect development tumors. relationship between tumors is diverse in different tissues genetic backgrounds. In this review, we provide basic knowledge pyroptosis, explain tumors, focus on significance tumor treatment. addition, further summarize possibility as a potential treatment strategy describe side effects radiotherapy chemotherapy caused by pyroptosis. brief, double-edged sword for rational use dual effect will help us explore formation ideas patients to develop new drugs based

Language: Английский

---

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

Annals of Oncology, Journal Year: 2020, Volume and Issue: 31(12), P. 1623 - 1649

Published: Sept. 23, 2020

Language: Английский

---

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

The Lancet, Journal Year: 2020, Volume and Issue: 396(10257), P. 1090 - 1100

Published: Sept. 20, 2020

Language: Английский

---

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

New England Journal of Medicine, Journal Year: 2022, Volume and Issue: 386(12), P. 1143 - 1154

Published: March 23, 2022

Trastuzumab emtansine is the current standard treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer whose disease progresses after a combination of anti-HER2 antibodies and taxane.We conducted phase 3, multicenter, open-label, randomized trial to compare efficacy safety trastuzumab deruxtecan (a HER2 antibody-drug conjugate) those in HER2-positive previously treated taxane. The primary end point was progression-free survival (as determined by blinded independent central review); secondary points included overall survival, objective response, safety.Among 524 randomly assigned patients, percentage who were alive without progression at 12 months 75.8% (95% confidence interval [CI], 69.8 80.7) 34.1% CI, 27.7 40.5) (hazard ratio or death from any cause, 0.28; 95% 0.22 0.37; P<0.001). 94.1% 90.3 96.4) 85.9% 80.9 89.7) death, 0.55; 0.36 0.86; prespecified significance boundary not reached). An response complete partial response) occurred 79.7% 74.3 84.4) received 34.2% 28.5 40.3) emtansine. incidence drug-related adverse events grade 98.1% 86.6% emtansine, 3 4 45.1% 39.8%, respectively. Adjudicated interstitial lung pneumonitis 10.5% group 1.9% group; none these 5.Among taxane, risk lower among than Treatment associated pneumonitis. (Funded Daiichi Sankyo AstraZeneca; DESTINY-Breast03 ClinicalTrials.gov number, NCT03529110.).

Language: Английский

---

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

Annals of Oncology, Journal Year: 2021, Volume and Issue: 32(10), P. 1216 - 1235

Published: July 6, 2021

Language: Английский

---

The lingering mysteries of metastatic recurrence in breast cancer

British Journal of Cancer, Journal Year: 2020, Volume and Issue: 124(1), P. 13 - 26

Published: Nov. 26, 2020

Despite being the hallmark of cancer that is responsible for highest number deaths, very little known about biology metastasis. Metastatic disease typically manifests after a protracted period undetectable following surgery or systemic therapy, owing to relapse recurrence. In case breast cancer, metastatic can occur months decades initial diagnosis and treatment. this review, we provide an overview key factors influence recurrence, with goal highlighting critical unanswered questions still need be addressed make difference in mortality patients.

Language: Английский

---

Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities

Molecular Cancer, Journal Year: 2020, Volume and Issue: 19(1)

Published: Nov. 24, 2020

Abstract Wnt signaling is a highly conserved pathway that plays critical role in controlling embryonic and organ development, as well cancer progression. Genome-wide sequencing gene expression profile analyses have demonstrated involved mainly the processes of breast proliferation metastasis. The most recent studies indicated also crucial immune microenvironment regulation, stemness maintenance, therapeutic resistance, phenotype shaping, etc. Wnt/β-Catenin, Wnt–planar cell polarity (PCP), Wnt–Ca 2+ are three well-established pathways share overlapping components play different roles In this review, we summarize main findings concerning relationship between provide an overview existing mechanisms, challenges, potential opportunities for advancing therapy diagnosis cancer.

Language: Английский

---

Understanding and overcoming resistance to PARP inhibitors in cancer therapy

Nature Reviews Clinical Oncology, Journal Year: 2021, Volume and Issue: 18(12), P. 773 - 791

Published: July 20, 2021

Language: Английский

---

Deciphering breast cancer: from biology to the clinic

Cell, Journal Year: 2023, Volume and Issue: 186(8), P. 1708 - 1728

Published: March 16, 2023

Language: Английский

---